Autoimmune Lung Disease Studies

​The Division of Rheumatology strives to understand more about autoimmune lung disease through research.  Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease. 

Study Name/IRB#/PI	​Brief Description	Basic Eligibility Criteria​	Contact
MINERAL; Microbiome and Neutrophil associated factors in Rheumatoid Arthritis and Autoimmune-related Interstitial Lung Disease 20-2769 Melissa Griffith, MD	An observational study to investigate the causes of chronic lung disease in rheumatoid arthritis and other autoimmune diseases	1. At least 18 years old 2. Falls under one of the following criteria: a. Diagnosis of scleroderma b. Diagnosis of idiopathic pulmonary fibrosis (IPF) or interstitial pneumonia with autoimmune features (IPAF) c. Diagnosis of RA with associated interstitial lung disease d. Diagnosis of RA with previous lung abnormalities seen on lung scan	RAStudies@cuanschutz.edu  303-724-0071
SAPPHIRE Study of the Association between Cellular Processes in the Lung & Blood and Patient Health in Individuals with Rheumatoid Arthritis with and without Evidence of Interstitial Lung Disease 23-0089 Kristen Demoruelle, MD, PhD	An observational study designed to learn more about the causes of Interstitial Lung Disease (ILD) in RA	At lease 18 years old and one of the following: Diagnosis of RA +/- associated ILD	RAStudies@cuanschutz.edu 303-724-7597 For more information visit: www.slayRA.com

Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length.  A visit to determine an individuals eligibility may be required.  A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.​